INFORMED CONSENT

I certify that the concerned person (patient, legal representative) has received genetic counseling according to the law on human genetic analysis (LAGH) on the various aspects of the described genetic analysis in the form "patient information". This person has given its consent and had enough time to ask questions and make its decision.

Patient decision on storage and use of the remaining biological material and analytical data for further analyses * = mandatory

- The patient agrees that his remaining biological material and analytical data will be stored for possible further analyses with his consent. Check "NO" means that the samples will be destroyed after analysis:  
- The patient agrees with the storage and anonymous use of his samples and analytical data for improvement of the quality of genetic analysis:  
- The patient agrees with the storage and anonymous use of his samples and analytical data for improvement of the quality of genetic analysis:

Use of patient sample and his analytical data for research purposes

- In principle, the patient agrees that his biological sample and analytical data could be kept and used for research purposes:  

At this point, his response does not imply any consent on his part.
NAME Firstname

ANALYSIS - Breast and ovarian cancer predisposition:

- DNA banking
- Screening of the three BRCA1/2 Ashkenazi Jewish founder mutations
- Specific mutation for breast and ovarian cancer (please specify which gene and mutation):
  - Family carrier already tested in our laboratory: Yes NAME, Firstname, N°DNA: No
  - Gene: ..............................................................
  - Mutation: ..........................................................

NGS Panels\textsuperscript{na}:
- BRCA1 and BRCA2 only (complete analysis)
- Breast Cancer gene panel (BRCA1, BRCA2, ATM, CHEK2, PALB2, PTEN, STK11, TP53)
- Ovarian Cancer gene panel (BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, RAD51D)
- Complete HBOC gene panel (ATM, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53)
- Additional/other genes:
  - CDH1
  - NBN
  - SMARCA4
  - BARD1

Sanger:
- HOXB13\textsuperscript{na} ×
- Other analysis (please specify below)\textsuperscript{na×}

**Complementary bioinformatics analysis for Complete HBOC gene panel from NGS data:**
(by 2 NGS techniques, one accredited, the other subjected to accreditation)

- ATM
- BARD1
- BRIP1
- CDH1
- CHEK2
- MLH1
- MSH2
- MSH6
- NBN
- PALB2
- PMS2
- PTEN
- RAD51C
- RAD51D
- SMARCA4
- STK11
- TP53

Please indicate here any additional helpful information:

\textbf{\texttimes} = the patient has been informed that the tests identified by the character \textbf{\texttimes} do not appear on the OFAS list in force and that they will therefore not necessarily be covered by the health insurance funds.

\textbf{na} = not accredited

NGS analysis is outside the accredited domain. The transition from "NGS per amplicon" technology to "NGS per capture" technology allows for better quality/sensitivity of analysis and an increased number of genes tested. The validation of this analysis is complete and the accreditation with the SAS is in progress.